YIJIA GROUP CORP. 8-K

What Happened

• Yijia Group Corp. (YJGJ) filed an 8‑K reporting that its Board and a majority of stockholders approved a name change to VitaNova Life Sciences Corporation and a reverse stock split at a ratio of 1-for-3. A Certificate of Amendment effecting the name change and the 1-for-3 reverse split was filed with the Nevada Secretary of State on January 9, 2026 and became effective that date. FINRA is currently processing the name change and the reverse split.
• Separately, the company previously increased its authorized share capital to 210,000,000 total shares (200,000,000 common; 10,000,000 preferred) via a Certificate of Amendment filed November 12, 2025, corrected a scrivener’s error on November 21, 2025, and on November 21, 2025 designated 3,000,000 shares of the preferred as Series A Preferred Stock.

Key Details

• Reverse split ratio: 1-for-3 — each shareholder will receive 1 share for every 3 shares owned (effective per the January 9, 2026 filing; FINRA processing ongoing).
• Name change: Yijia Group Corp. -> VitaNova Life Sciences Corporation; Certificate of Amendment filed January 9, 2026.
• Authorized shares after amendment: 210,000,000 total (200,000,000 common; 10,000,000 preferred).
• Series A Preferred: 3,000,000 shares of the authorized preferred designated as Series A Preferred (Certificate of Designation filed November 21, 2025).
• New CUSIP for common stock: 98585W403; ticker symbol change is intended but still under evaluation.

Why It Matters

• The reverse split will consolidate the company’s outstanding common shares (reducing share count by a factor of three) and will change per‑share metrics (e.g., share price and earnings per share will adjust accordingly). Shareholders should see their share balances updated to reflect one new share for every three old shares once FINRA and the market process the change.
• Increasing authorized shares and creating blank‑check preferred stock (with 3,000,000 Series A designated) gives the company greater flexibility to raise capital or issue preferred shares in the future, which could dilute common shareholders if used.
• The legal filings are complete and FINRA processing is pending; investors should watch for FINRA approval, the company’s announced effective trading date, and the new ticker symbol before trading or making decisions. The filing does not report financial results or management changes.